Birchview Capital LP Lowers Stock Holdings in Coherus BioSciences, Inc. (NASDAQ:CHRS)

Birchview Capital LP reduced its stake in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS - Free Report) by 78.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 82,000 shares of the biotechnology company's stock after selling 290,000 shares during the period. Birchview Capital LP owned 0.07% of Coherus BioSciences worth $113,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the stock. Los Angeles Capital Management LLC increased its stake in shares of Coherus BioSciences by 20.0% in the fourth quarter. Los Angeles Capital Management LLC now owns 1,116,142 shares of the biotechnology company's stock worth $1,540,000 after purchasing an additional 186,010 shares during the period. Geode Capital Management LLC raised its stake in shares of Coherus BioSciences by 7.7% in the third quarter. Geode Capital Management LLC now owns 2,565,145 shares of the biotechnology company's stock worth $2,668,000 after acquiring an additional 182,914 shares during the last quarter. Savant Capital LLC acquired a new position in Coherus BioSciences during the 4th quarter worth $130,000. Bank of New York Mellon Corp boosted its holdings in Coherus BioSciences by 26.6% in the fourth quarter. Bank of New York Mellon Corp now owns 391,002 shares of the biotechnology company's stock valued at $540,000 after acquiring an additional 82,222 shares during the last quarter. Finally, MetLife Investment Management LLC acquired a new stake in shares of Coherus BioSciences during the 4th quarter worth approximately $101,000. Institutional investors and hedge funds own 72.82% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on CHRS shares. HC Wainwright reiterated a "buy" rating and issued a $7.00 target price on shares of Coherus BioSciences in a report on Tuesday. UBS Group reaffirmed a "neutral" rating and set a $1.05 price target (down previously from $1.50) on shares of Coherus BioSciences in a research report on Thursday, April 24th. Finally, StockNews.com lowered Coherus BioSciences from a "hold" rating to a "sell" rating in a research note on Tuesday, April 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $5.26.

Coherus BioSciences Trading Down 2.4 %

CHRS stock traded down $0.03 during trading on Thursday, hitting $1.01. The company had a trading volume of 615,938 shares, compared to its average volume of 2,717,840. Coherus BioSciences, Inc. has a one year low of $0.66 and a one year high of $2.43. The business has a 50-day moving average of $0.96 and a 200-day moving average of $1.12. The stock has a market cap of $116.48 million, a PE ratio of -12.56 and a beta of 1.01.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.